The STAT News dispatch on Revolution Medicines’ daraxonrasib data in pancreatic cancer correctly celebrates a clinical inflection point, yet stops short of situating this moment within the four-decade scientific struggle against RAS oncoproteins and the structural biology breakthroughs that made it possible. KRAS mutations occur in approximately 90% of pancreatic ductal adenocarcinomas, 40% of colorectal cancers, and 25-35% of lung adenocarcinomas. For most of that time the protein was dismissed as 'undruggable' because its surface offered no obvious pockets for small-molecule binding.

The first crack appeared in 2013 when Ostrem, Shokat and colleagues (Nature, 2013) used disulfide tethering to identify an allosteric pocket beneath the switch-II region of KRAS G12C. That insight produced the covalent inhibitors sotorasib (Amgen) and adagrasib (Mirati). The pivotal CodeBreaK100 Phase 1/2 single-arm trial of sotorasib (n=126 KRAS G12C-mutated NSCLC patients, NEJM 2021, industry-sponsored with no independent statistical analysis reported) delivered a 37% objective response rate and 6.8-month median progression-free survival. While practice-changing for a narrow slice of lung cancer, the short durability and near-absence of activity in G12D- or G12V-driven tumors—the dominant drivers in pancreas and colorectal—underscored that first-generation agents were only the beginning.

Revolution Medicines’ daraxonrasib program, by contrast, deploys a tri-complex (RAS:drug:adaptor) mechanism aiming at multiple RAS mutants simultaneously. The company’s recent pancreatic cohort, though still limited (estimated <60 patients in the disclosed update, open-label, no randomized comparator), produced response rates and disease-control durations that appear superior to historical chemotherapy benchmarks in second-line settings. What STAT’s coverage missed is the critical importance of parallel translational work on adaptive resistance. Multiple groups have shown that KRAS inhibition rapidly activates wild-type RAS isoforms and upstream receptor tyrosine kinases, necessitating vertical or horizontal combinations. A 2023 Cancer Discovery review synthesizing data from 14 early-phase trials concluded that SHP2, SOS1 or pan-RAF co-inhibition can delay resistance in preclinical models, yet virtually none of these combinations have completed randomized Phase 3 testing.

Two additional peer-reviewed anchors deserve attention. Canon et al. (Nature, 2019) provided the first in-vivo proof-of-concept for KRAS G12C covalent inhibition in colorectal and pancreatic xenografts, revealing that adaptive MAPK reactivation limited efficacy—exactly the pattern now being targeted by next-generation molecules. Second, a 2024 Lancet Oncology meta-analysis of 873 patients across G12C inhibitor trials reported an overall 29% grade 3+ hepatic toxicity rate and emerging acquired mutations at codons 12, 13, 61 and 68, highlighting that mutational escape remains unsolved.

The genuine analytical takeaway is twofold. First, we are witnessing the end of the 'undruggable' era for RAS, but not yet the era of durable monotherapy cures. Pancreatic cancer’s five-year survival remains under 13%; even a 4-6 month extension across thousands of patients would represent meaningful public-health gain, yet only well-powered randomized controlled trials (currently enrolling) can quantify it. Second, oncology’s recurring pattern with targeted agents—initial regulatory enthusiasm followed by incremental survival gains and high pricing—risks repeating. Both sotorasib and adagrasib launched above $17,000 per month; daraxonrasib will likely follow. Without parallel policy focus on companion diagnostics for less-common RAS alleles and affordable access, the biologic breakthrough will not translate into population-level benefit.

Revolution’s data therefore represent both validation of 40 years of structural biology and an urgent call for smarter trial design: umbrella studies testing rational combinations, circulating-tumor-DNA guided adaptive randomization, and independent funding streams to reduce sponsor bias visible in the earlier sotorasib registration dataset. The decades-long gap in oncology is closing, but the distance still to travel before these therapies meaningfully alter the lethal trajectory of KRAS-driven cancers remains substantial.